Skip to main content

Table 4 Univariable and multivariable Cox proportional hazard regression analyses of overall survival

From: Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience

FactorUnivariable analysisPMultivariable analysisP
HR (95%CI)HR (95% CI)
Gender
 MaleReference  
 Female1.376 (0.766–2.472)0.286
Age at diagnosis
 < 30yReference  
 ≥ 30 y1.450(0.839–2.507)0.183
Primary site
 ExtremityReference  
 Trunk1.105 (0.620–1.971)0.735
Tumor origin
 SkeletalReference  
 Extraskeletal0.660 (0.346–1.261)0.209
Stage
 LocalizedReference  Reference 
 Metastatic2.269 (1.294–3.976)0.0042.488 (1.413–4.383)0.002
Diameter of primary tumor
 < 8 cmReference  
 ≥ 8 cm0.765 (0.434–1.351)0.356
Local therapy
 SurgeryReference  
 Radiotherapy1.327 (0.654–2.692)0.432
 Surgery + radiotherapy1.271 (0.679–2.379)0.453
Time to local therapy0.901 (0.733–1.107)0.329
Number of chemotherapy cycles
 < 12Reference Reference0.003
 ≥ 120.505 (0.291–0.874)0.015 0.424 (0.240–0.748) 
Frequency of chemotherapy delays
 ≥ 25%Reference Reference 
 < 25%0.537 (0.270–1.067)0.076 0.438 (0.217–0.887)0.022
Grade 3–4 chemotherapy toxicity
 YESReference0.610 
 NO0.595(0.081–4.359) 
Administration of dexrazoxane
 YESReference  
 NO0.938(0.540–1.628)0.820
  1. HR Hazard ratio, CI Confidence interval
\